96 related articles for article (PubMed ID: 11535128)
1. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.
Høyer-Hansen G; Pessara U; Holm A; Pass J; Weidle U; Danø K; Behrendt N
Biochem J; 2001 Sep; 358(Pt 3):673-9. PubMed ID: 11535128
[TBL] [Abstract][Full Text] [Related]
2. Affinity Purification of Glycosylphosphatidylinositol-anchored Proteins by Alpha-Toxin.
Huang K; Park S
Methods Mol Biol; 2022; 2303():251-257. PubMed ID: 34626384
[TBL] [Abstract][Full Text] [Related]
3. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation.
Rasmussen LJH; Petersen JEV; Eugen-Olsen J
Front Immunol; 2021; 12():780641. PubMed ID: 34925360
[TBL] [Abstract][Full Text] [Related]
4. Soluble Urokinase Plasminogen Activator Receptor: Genetic Variation and Cardiovascular Disease Risk in Black Adults.
Olson NC; Raffield LM; Moxley AH; Miller-Fleming TW; Auer PL; Franceschini N; Ngo D; Thornton TA; Lange EM; Li Y; Nickerson DA; Zakai NA; Gerszten RE; Cox NJ; Correa A; Mohlke KL; Reiner AP
Circ Genom Precis Med; 2021 Dec; 14(6):e003421. PubMed ID: 34706549
[TBL] [Abstract][Full Text] [Related]
5. Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder.
Dohn LH; Thind P; Salling L; Lindberg H; Oersted S; Christensen IJ; Laerum OD; Illemann M; von der Maase H; Høyer-Hansen G; Pappot H
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34069121
[TBL] [Abstract][Full Text] [Related]
6. The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications.
Li Santi A; Napolitano F; Montuori N; Ragno P
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923400
[TBL] [Abstract][Full Text] [Related]
7. Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.
Harel E; Shoji J; Abraham V; Miller L; Laszik ZG; King A; Dobi D; Szabo G; Hann B; Sarwal MM; Craik CS; Vincenti F
Transplantation; 2020 Jan; 104(1):54-60. PubMed ID: 31449183
[TBL] [Abstract][Full Text] [Related]
8. Can components of the plasminogen activation system predict the outcome of kidney transplants?
Jankun J; Khan OA; Mostafa HI; Sindhwani P; Skrzypczak-Jankun E
Cent Eur J Immunol; 2018; 43(2):222-230. PubMed ID: 30135637
[TBL] [Abstract][Full Text] [Related]
9. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
[TBL] [Abstract][Full Text] [Related]
10. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
Chen JS; Chang LC; Wu CZ; Tseng TL; Lin JA; Lin YF; Cheng CW
J Biomed Sci; 2016 Feb; 23():24. PubMed ID: 26846181
[TBL] [Abstract][Full Text] [Related]
11. Epithelial and stromal cell urokinase plasminogen activator receptor expression differentially correlates with survival in rectal cancer stages B and C patients.
Ahn SB; Chan C; Dent OF; Mohamedali A; Kwun SY; Clarke C; Fletcher J; Chapuis PH; Nice EC; Baker MS
PLoS One; 2015; 10(2):e0117786. PubMed ID: 25692297
[TBL] [Abstract][Full Text] [Related]
12. Ligand binding alters dimerization and sequestering of urokinase receptors in raft-mimicking lipid mixtures.
Ge Y; Siegel AP; Jordan R; Naumann CA
Biophys J; 2014 Nov; 107(9):2101-11. PubMed ID: 25418095
[TBL] [Abstract][Full Text] [Related]
13. Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes.
Magnussen S; Hadler-Olsen E; Latysheva N; Pirila E; Steigen SE; Hanes R; Salo T; Winberg JO; Uhlin-Hansen L; Svineng G
PLoS One; 2014; 9(8):e105929. PubMed ID: 25157856
[TBL] [Abstract][Full Text] [Related]
14. The urokinase receptor takes control of cell migration by recruiting integrins and FPR1 on the cell surface.
Gorrasi A; Li Santi A; Amodio G; Alfano D; Remondelli P; Montuori N; Ragno P
PLoS One; 2014; 9(1):e86352. PubMed ID: 24466048
[TBL] [Abstract][Full Text] [Related]
15. A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.
Nieves EC; Manchanda N
J Biol Chem; 2010 Apr; 285(17):12595-603. PubMed ID: 20177061
[TBL] [Abstract][Full Text] [Related]
16. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.
Lomholt AF; Høyer-Hansen G; Nielsen HJ; Christensen IJ
Br J Cancer; 2009 Sep; 101(6):992-7. PubMed ID: 19672256
[TBL] [Abstract][Full Text] [Related]
17. Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Sloand EM; Pfannes L; Scheinberg P; More K; Wu CO; Horne M; Young NS
Exp Hematol; 2008 Dec; 36(12):1616-24. PubMed ID: 18954937
[TBL] [Abstract][Full Text] [Related]
18. Models, mechanisms and clinical evidence for cancer dormancy.
Aguirre-Ghiso JA
Nat Rev Cancer; 2007 Nov; 7(11):834-46. PubMed ID: 17957189
[TBL] [Abstract][Full Text] [Related]
19. The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis.
Leduc D; Beaufort N; de Bentzmann S; Rousselle JC; Namane A; Chignard M; Pidard D
Infect Immun; 2007 Aug; 75(8):3848-58. PubMed ID: 17517866
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
